This Article Full Text Full Text (PDF) All Versions of this Article: 91/4/1229    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olney, R. C. Articles by Warman, M. L. Search for Related Content PubMed PubMed Citation Articles by Olney, R. C. Articles by Warman, M. L. Related Collections Pediatric Endocrinology

Heterozygous Mutations in Natriuretic Peptide Receptor-B (NPR2) Are Associated with Short Stature

Division of Endocrinology (R.C.O.), Nemours Children’s Clinic, Jacksonville, Florida 32207; Departments of Epidemiology and Biostatistics (H.B., M.L.W.), Genetics (C.F.B.), and Pediatrics (M.L.W.), Case Western Reserve University School of Medicine, Cleveland, Ohio 44106; Department of Medicine (T.C.R.P., E.A.E.), Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand; and Department of Biochemistry, Molecular Biology, and Biophysics (L.R.P.), University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455

Address all correspondence and requests for reprints to: Robert C. Olney, M.D., Division of Endocrinology, Nemours Children’s Clinic, Jacksonville, Florida 32207. E-mail: rolney{at}nemours.org.

Abstract

Context: C-type natriuretic peptide (CNP) is an important regulator of skeletal growth. Loss-of-function mutations affecting the CNP receptor natriuretic peptide receptor-B (gene NPR2) cause the autosomal recessive skeletal dysplasia, acromesomelic dysplasia, Maroteaux type (AMDM). The phenotype of heterozygous carriers of NPR2 mutations is less clear.

Objective: The objective of the study was to determine the phenotypic features of heterozygous carriers of NPR2 mutations.

Design and Setting: This was a case-control study from the general community.

Subjects: Thirty-nine members of a family in which one member has AMDM were studied.

Intervention: This was an observational study.

Main Outcome Measure: The primary measure was stature, with the hypothesis that carriers have reduced stature compared with noncarriers.

Results: Sixteen family members were NPR2 mutation carriers. Height z-scores of these carriers were –1.8 ± 1.1 (mean ± SD), which was significantly less than the 23 noncarrier family members (–0.4 ± 0.8, P < 0.0005) and the general population (P < 0.0005). However, there was no difference in body proportion between carriers and noncarriers. The proband with AMDM had low IGF-I levels and evidence of GH resistance, as well as very high plasma levels of CNP and its amino-terminal propeptide. Levels of these peptides were normal in the heterozygous carriers.

Conclusions: We have shown that heterozygous mutations in NPR2 are associated with short stature. Assuming one in 700 people unknowingly carry an NPR2 mutation, our data suggest that approximately one in 30 individuals with idiopathic short stature are carriers of NPR2 mutations.

This article has been cited by other articles:

				R. Hachiya, Y. Ohashi, Y. Kamei, T. Suganami, H. Mochizuki, N. Mitsui, M. Saitoh, M. Sakuragi, G. Nishimura, H. Ohashi, et al. Intact Kinase Homology Domain of Natriuretic Peptide Receptor-B Is Essential for Skeletal Development J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 4009 - 4014. [Abstract] [Full Text] [PDF]

				A. Woods, S. Khan, and F. Beier C-Type Natriuretic Peptide Regulates Cellular Condensation and Glycosaminoglycan Synthesis during Chondrogenesis Endocrinology, October 1, 2007; 148(10): 5030 - 5041. [Abstract] [Full Text] [PDF]

				T. C. R. Prickett, C. W. H. Rumball, A. J. Buckley, F. H. Bloomfield, T. G. Yandle, J. E. Harding, and E. A. Espiner C-Type Natriuretic Peptide Forms in the Ovine Fetal and Maternal Circulations: Evidence for Independent Regulation and Reciprocal Response to Undernutrition Endocrinology, August 1, 2007; 148(8): 4015 - 4022. [Abstract] [Full Text] [PDF]

				J. Baron Growth Hormone Therapy in Childhood: Titration Versus Weight-Based Dosing? J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2436 - 2438. [Full Text] [PDF]

				R. M. C. Pereira, M. H. Aguiar-Oliveira, A. Sagazio, C. R. P. Oliveira, F. T. Oliveira, V. C. Campos, C. T. Farias, T. A. R. Vicente, M. B. Gois Jr, J. L. M. Oliveira, et al. Heterozygosity for a Mutation in the Growth Hormone-Releasing Hormone Receptor Gene Does Not Influence Adult Stature, But Affects Body Composition J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2353 - 2357. [Abstract] [Full Text] [PDF]

				K. D. Rodgers, T. Sasaki, A. Aszodi, and O. Jacenko Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome Hum. Mol. Genet., March 1, 2007; 16(5): 515 - 528. [Abstract] [Full Text] [PDF]

				A. Dempfle, S. A. Wudy, K. Saar, S. Hagemann, S. Friedel, A. Scherag, L. D. Berthold, G. Alzen, L. Gortner, W. F. Blum, et al. Evidence for involvement of the vitamin D receptor gene in idiopathic short stature via a genome-wide linkage study and subsequent association studies Hum. Mol. Genet., September 15, 2006; 15(18): 2772 - 2783. [Abstract] [Full Text] [PDF]

				S. A. DiVall and S. Radovick Deciphering the genetics of stature--another piece of the puzzle. J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1218 - 1219. [Full Text] [PDF]